Akums Drugs & Pharmaceuticals Ltd., India’s largest Contract Development and Manufacturing Organization (CDMO), has achieved a major regulatory milestone by securing approval from the Drug Controller General of India (DCGI) for its Colchicine 0.5 mg tablets. This first-time-in-India approval significantly expands the company's preventive cardiology and cardiovascular portfolio.

The newly approved formulation is specifically indicated to lower the risk of stroke, myocardial infarction, cardiovascular death, and coronary revascularisation in adult patients suffering from established atherosclerotic disease or multiple cardiovascular risk factors.

According to Pharmarack, the Indian Pharmaceutical Market (IPM) grew 10.7% year-on-year in August 2026 to Rs. 23,272 crore. Chronic therapies continued to be an important growth driver, reflecting the increasing demand associated with long-term disease management. The cardiac segment has emerged as one of the key contributors to this growth. In July 2026, the cardiac therapy market recorded 14.7% year-on-year growth and sales of approximately ₹3,299 crore, according to Pharmarack.

Colchicine is a well-established anti-inflammatory agent that works through mechanisms including inhibition of microtubule polymerisation and modulation of inflammatory signalling pathways. Akums’ approved 0.5 mg formulation is indicated to reduce the risk of myocardial infarction, stroke, coronary revascularisation and cardiovascular death in adult patients with established atherosclerotic disease or multiple cardiovascular risk factors.

The product information identifies mechanisms including inhibition of NLRP3 inflammasome activation, reduction of neutrophil activation and migration, and suppression of endothelial inflammation—pathways associated with vascular inflammation and atherosclerotic plaque vulnerability.

Sanjeev Jain, Managing Director, Akums Drugs & Pharmaceuticals Ltd., said: “Cardiovascular disease represents one of the most important healthcare challenges facing India, and the focus of treatment is increasingly moving towards comprehensive and long-term risk management. The DCGI approval of Colchicine 0.5 mg reflects Akums’ commitment to enabling differentiated therapies that address evolving areas of medical need. We are leveraging our scientific, regulatory and manufacturing capabilities to support the availability of relevant therapeutic options for physicians and patients.”

Sandeep Jain, Managing Director, Akums Drugs & Pharmaceuticals Ltd., said: “The continued growth of the cardiac therapy segment reflects growing emphasis on chronic disease management. Colchicine 0.5 mg strengthens our cardiovascular portfolio by addressing the inflammatory component of cardiovascular risk.. This approval is aligned with our broader strategy of developing and enabling high-quality pharmaceutical solutions in therapeutic areas where there is significant unmet or evolving healthcare need.”

The market opportunity is supported not only by India's growing cardiovascular disease burden but also by the country's expanding focus on early screening, diagnosis and chronic disease management. The Government of India has increasingly strengthened its NCD infrastructure and preventive-health programmes, creating a broader ecosystem for long-term management of cardiovascular and metabolic diseases.